샘플 요청 목록

 카트 문의
시장보고서
상품코드
1760954

세계의 마이크로 RNA(miRNA) 시장

microRNA (miRNA)
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 379 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

마이크로 RNA(miRNA) 세계 시장은 2030년까지 8억 2,910만 달러에 달할 전망

2024년에 3억 9,620만 달러로 추정되는 마이크로 RNA(miRNA) 세계 시장은 2024년부터 2030년까지 CAGR 13.1%로 성장하여 2030년에는 8억 2,910만 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석하고 있는 부문 중 하나인 제품은 CAGR 11.4%를 기록하며 분석 기간 종료시에는 4억 1,180만 달러에 달할 것으로 예측됩니다. 서비스 분야의 성장률은 분석 기간 동안 CAGR 14.9%로 추정됩니다.

미국 시장은 1억 5,430만 달러로 추정, 중국은 CAGR 16.3%로 성장 예측

미국의 마이크로 RNA(miRNA) 시장은 2024년에 1억 5,430만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 8,820만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 16.3%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 11.1%와 11.2%로 예측됩니다. 유럽에서는 독일이 CAGR 11.8%로 성장할 것으로 예측됩니다.

세계의 마이크로 RNA(miRNA) 시장 - 주요 동향과 촉진요인 정리

마이크로 RNA(miRNA)는 저분자 비암호화 RNA 분자의 일종으로, 전사 후 수준에서 유전자 발현 조절에 중요한 역할을 합니다. 일반적으로 약 22 뉴클레오티드 길이의 miRNA는 표적 메신저 RNA(mRNA) 전사체의 상보적 서열에 결합하여 일반적으로 번역 억제 또는 표적 분해를 통해 유전자 침묵을 초래하며, miRNA의 발견은 유전자가 세포 내에서 어떻게 조절되는지에 대한 이해를 크게 진전시켰습니다. 발생, 분화, 대사를 포함한 광범위한 생물학적 과정에 영향을 미치고 있습니다. 또한, 다양한 세포 내 경로에 관여하기 때문에 miRNA는 많은 질병, 특히 암, 심혈관질환, 신경 퇴행성 질환의 병태생리에도 중요한 역할을 하는 것으로 알려져 있습니다.

miRNA에 대한 연구가 급증하고 있으며, 질병의 진단 및 예후 바이오마커로서, 그리고 치료적 개입의 표적으로서의 잠재력이 밝혀지고 있으며, miRNA를 연구하기 위한 도구와 기술도 진화하고 있습니다. 바이오인포매틱스 도구에 이르기까지 다양합니다. 임상적 측면에서, miRNA 기반 진단은 특정 질환과 관련된 특정 miRNA를 식별하여 조기 발견 및 보다 맞춤화된 치료 계획으로 이어질 수 있는 가능성을 제시합니다. 또한, 특정 miRNA의 기능을 조절하는 것을 목표로 하는 miRNA 치료제의 개발도 진행되고 있으며, 일부 후보물질은 전임상 및 임상시험 단계에 있습니다. 이러한 치료 전략에는 세포의 정상 기능을 회복하도록 설계된 합성 miRNA인 miRNA 모방체와 질병 진행에 관여하는 miRNA의 기능을 억제하는 miRNA 억제제가 포함됩니다.

miRNA 시장의 성장은 miRNA 프로파일링 기술의 발전, miRNA 연구 및 치료제 개발에 대한 투자 증가, 정밀의료에서 miRNA의 잠재력에 대한 인식 증가 등 여러 요인에 의해 주도되고 있습니다. 기술의 발전으로 miRNA의 검출 및 정량화가 보다 효율적이고 비용 효율적인 방식으로 이루어지면서 연구 및 임상 분야 모두에서 miRNA의 적용 가능성이 높아지고 있습니다. 제약 및 생명공학 분야는 질병 경로의 여러 측면을 표적으로 삼을 수 있는 miRNA의 능력에 매료되어 miRNA 기반 치료제 개발에 점점 더 많은 노력을 기울이고 있습니다. 또한, 헬스케어 산업이 보다 개인화된 치료법을 추구함에 따라 miRNA 진단 및 치료제에 대한 수요가 증가할 것으로 예상됩니다. 이러한 추세는 특정 miRNA를 특정 질병과 연관시키는 연구가 증가함에 따라 바이오마커 및 치료 표적으로서의 miRNA의 임상적 가치를 더욱 뒷받침하고 있습니다.

부문

제품 유형(제품, 서비스), 용도(암, 감염증, 면역질환, 심혈관질환, 신경질환, 기타 용도), 최종 용도(학술·정부 연구기관, 바이오테크놀러지·제약 기업, 기타 최종 용도)

조사 대상 기업 사례(총 64개사)

  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Abcam PLC
  • BioVendor-Laboratorni medicina a.s
  • GeneCopoeia, Inc.
  • AKESOgen, Inc.
  • Entos Pharmaceuticals
  • Genomnia
  • Guangzhou Ruibo Biotechnology Co., Ltd.
  • 20Med Therapeutics
  • AceRNA Technologies Co., Ltd.
  • AptamiR Therapeutics
  • Causeway Therapeutics
  • Cardior Pharmaceuticals
  • Craif

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범에 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계의 전문가에서 큐레이트 된 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • MIRNA 응용에 관한 인사이트
  • 암
  • 심장병
  • 신장병
  • 신경계
  • 알코올 중독
  • 비만
  • 지혈
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

ksm 25.07.07

Global microRNA (miRNA) Market to Reach US$829.1 Million by 2030

The global market for microRNA (miRNA) estimated at US$396.2 Million in the year 2024, is expected to reach US$829.1 Million by 2030, growing at a CAGR of 13.1% over the analysis period 2024-2030. Products, one of the segments analyzed in the report, is expected to record a 11.4% CAGR and reach US$411.8 Million by the end of the analysis period. Growth in the Services segment is estimated at 14.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$154.3 Million While China is Forecast to Grow at 16.3% CAGR

The microRNA (miRNA) market in the U.S. is estimated at US$154.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$88.2 Million by the year 2030 trailing a CAGR of 16.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.1% and 11.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.8% CAGR.

Global microRNA (miRNA) Market - Key Trends and Drivers Summarized

MicroRNAs (miRNAs) are a class of small, non-coding RNA molecules that play a crucial role in regulating gene expression at the post-transcriptional level. Typically about 22 nucleotides long, miRNAs bind to complementary sequences on target messenger RNA (mRNA) transcripts, usually resulting in gene silencing via translational repression or target degradation. The discovery of miRNAs has significantly advanced our understanding of how genes are regulated in cells and has implications for a wide range of biological processes including development, differentiation, and metabolism. Given their involvement in various cellular pathways, miRNAs are also considered vital in the pathology of numerous diseases, notably cancer, cardiovascular diseases, and neurodegenerative disorders.

Research into miRNAs has burgeoned, revealing their potential as biomarkers for disease diagnosis and prognosis, as well as targets for therapeutic intervention. Tools and technologies to study miRNAs have also evolved, ranging from advanced sequencing techniques to bioinformatics tools designed to predict miRNA targets and functions. In the clinical context, miRNA-based diagnostics have shown promise in identifying specific miRNAs associated with particular disease states, which can lead to early detection and more personalized treatment plans. Moreover, miRNA therapeutics, which aim to modulate the function of specific miRNAs, are in development, with several candidates in preclinical and clinical trials. These therapeutic strategies include miRNA mimics, which are synthetic miRNAs designed to restore normal function to cells, and miRNA inhibitors, which block the function of miRNAs involved in disease progression.

The growth in the miRNA market is driven by several factors, including advances in miRNA profiling technologies, increased investment in miRNA research and therapeutic development, and a growing awareness of the potential of miRNAs in precision medicine. Technological advancements have led to more efficient and cost-effective methods for detecting and quantifying miRNAs, enhancing their applicability in both research and clinical settings. The pharmaceutical and biotechnological sectors are increasingly focusing on developing miRNA-based therapeutics, attracted by their ability to target multiple aspects of disease pathways. Moreover, as the healthcare industry moves toward more personalized treatment options, the demand for miRNA diagnostics and therapeutics is expected to rise, reflecting their potential to tailor treatments to individual genetic profiles and disease conditions. This trend is bolstered by a growing body of research that links specific miRNAs to particular diseases, further underpinning the clinical value of miRNAs as both biomarkers and therapeutic targets.

SCOPE OF STUDY:

The report analyzes the microRNA (miRNA) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Products, Services); Application (Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases, Other Applications); End-Use (Academic & Government Research Institutes, Biotech & Pharma Companies, Other End-Uses)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Select Competitors (Total 64 Featured) -

  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Abcam PLC
  • BioVendor - Laboratorni medicina a.s
  • GeneCopoeia, Inc.
  • AKESOgen, Inc.
  • Entos Pharmaceuticals
  • Genomnia
  • Guangzhou Ruibo Biotechnology Co., Ltd.
  • 20Med Therapeutics
  • AceRNA Technologies Co., Ltd.
  • AptamiR Therapeutics
  • Causeway Therapeutics
  • Cardior Pharmaceuticals
  • Craif

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • microRNA (miRNA) - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • A Prelude to MicroRNA
    • Global Market Prospects and Outlook
    • Global miRNA Market Set to Witness Rapid Growth
    • Disease Diagnostics Segment Leads the Market
    • MicroRNAs Likely to Be Instrumental in Disease Diagnosis and Treatment
    • Polymerase Chain Reaction (PCR) Dominates the Instruments Category
    • Academic and Government Research Institutes Holds the Largest Share
    • North America Dominates Global miRNA Market, Asia-Pacific to Witness Steady Growth
    • Competition
    • Increasing Emphasis on R&D by Players to Boost Market Growth
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Incidence of Infectious Diseases and Chronic Conditions to Help miRNA Market Gallop Ahead
    • Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    • Increasing Application in Cancer Diagnostics as Biomarkers to Drive Market Growth
    • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • The Future of miRNA-based Cancer Biomarkers
    • Consistent Increase in Risks and Threats from Infections Drive Healthy Market Growth
    • Global Number of Deaths Caused Due to Communicable Diseases (In 000s)
    • Infectious Diseases Related Mortality High Among Children below 5 Years: Breakdown of Leading Causes of Death in Children below 5 Years (in %)
    • MicroRNA Biomarkers Hold Promise for Diagnosis of Infectious Diseases
    • Focus on Development of miRNA-based Therapeutics Bodes Well for Market Growth
    • Increasing Investments in miRNA to Bolster Market Growth
    • Diagnostics and Therapeutics Investments
    • Standard Methods Utilized to measure miRNA Biomarkers
    • Advancements in Detection Methodologies Focus on Enhancing Sensitivity and Selectivity of miRNA Detection
    • Increasing Demand for Liquid Biopsies to Drive the MicroRNA Market
    • miRNA by Type of Gastrointestinal Cancers
    • Circulating miRNAs as Cancer Detectors
    • Aging Demographics Add to the Global Burden of Chronic Diseases, Presenting Opportunities for the Market
    • Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030
    • Growing Global Healthcare Spending and Supportive Government Initiatives Boost Market Prospects
    • miRNA and Next Generation Sequencing
    • Market Restraints
  • AN INSIGHT INTO MIRNA APPLICATIONS
  • CANCER
    • Role of miRNA in Cancer Cell
    • DNA Repair and Cancer
  • HEART DISEASE
    • miRNA-712
    • Human Homolog-microRNA-205
  • KIDNEY DISEASE
  • NERVOUS SYSTEM
    • Stroke
  • ALCOHOLISM
  • OBESITY
  • HEMOSTASIS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 3: World 14-Year Perspective for Products by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 6: World 14-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 9: World 14-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 12: World 14-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Immunological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Immunological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 15: World 14-Year Perspective for Immunological Disorders by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 18: World 14-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Neurological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Neurological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 21: World 14-Year Perspective for Neurological Diseases by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 24: World 14-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2025 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Academic & Government Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Academic & Government Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 27: World 14-Year Perspective for Academic & Government Research Institutes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Biotech & Pharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Biotech & Pharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 30: World 14-Year Perspective for Biotech & Pharma Companies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2025 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 33: World 14-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2025 & 2030
    • TABLE 34: World microRNA (miRNA) Market Analysis of Annual Sales in US$ Thousand for Years 2016 through 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for microRNA (miRNA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for microRNA (miRNA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 37: World 14-Year Perspective for microRNA (miRNA) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2016, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • microRNA (miRNA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 40: USA 14-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 43: USA 14-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 46: USA 14-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 49: Canada 14-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 52: Canada 14-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 55: Canada 14-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2025 & 2030
  • JAPAN
    • microRNA (miRNA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 58: Japan 14-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 61: Japan 14-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 64: Japan 14-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2025 & 2030
  • CHINA
    • microRNA (miRNA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 67: China 14-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 70: China 14-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 73: China 14-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2025 & 2030
  • EUROPE
    • microRNA (miRNA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 76: Europe 14-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 79: Europe 14-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 82: Europe 14-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for microRNA (miRNA) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for microRNA (miRNA) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 85: Europe 14-Year Perspective for microRNA (miRNA) by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2016, 2025 & 2030
  • FRANCE
    • microRNA (miRNA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 88: France 14-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 91: France 14-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 94: France 14-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2025 & 2030
  • GERMANY
    • microRNA (miRNA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 97: Germany 14-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 100: Germany 14-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 103: Germany 14-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2025 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 106: Italy 14-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 109: Italy 14-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 112: Italy 14-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2025 & 2030
  • UNITED KINGDOM
    • microRNA (miRNA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 115: UK 14-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 118: UK 14-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 121: UK 14-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2025 & 2030
  • REST OF EUROPE
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Europe Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 124: Rest of Europe 14-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2025 & 2030
    • TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Europe Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 127: Rest of Europe 14-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2025 & 2030
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Europe Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 130: Rest of Europe 14-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2025 & 2030
  • ASIA-PACIFIC
    • microRNA (miRNA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Asia-Pacific Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 133: Asia-Pacific 14-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2025 & 2030
    • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Asia-Pacific Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 136: Asia-Pacific 14-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2025 & 2030
    • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Asia-Pacific Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 139: Asia-Pacific 14-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2025 & 2030
  • REST OF WORLD
    • TABLE 140: Rest of World Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of World Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 142: Rest of World 14-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2025 & 2030
    • TABLE 143: Rest of World Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of World Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 145: Rest of World 14-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2025 & 2030
    • TABLE 146: Rest of World Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of World Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 148: Rest of World 14-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제